Efficacy and Safety Study of BLX-028914 in Subjects With Allergic Rhinitis

Inclusion criteria

• 18 to 50 years of age (inclusive), male or female
• Body Mass Index (BMI) between 18 and 28 kg/m2 (inclusive)
• History of pollen-induced seasonal allergic rhinitis but otherwise healthy
• Positive skin prick test for timothy and/or birch allergen
• Sufficient reaction to nasally administered allergen at screening
• Signed informed consent obtained

Exclusion criteria

• Expected symptoms of seasonal allergic rhinitis during the study period
• Asthma
• Nasal anatomical deviations, ongoing nasal symptoms, ongoing upper respiratory tract infection
• Anti-allergy immunotherapy in the previous two years
• Extensive use of nasal sprays
• Any medication except for contraceptives, during their last five half- lives prior to the first treatment period except for occasional OTC analgesics
• Ingestion of grapefruit or grapefruit juice or herbal remedies (e.g. St John's-wort) that may effect the enzyme CYP3A4
• Smoking within 3 months of first treatment period
• Clinically significant laboratory findings
• Pregnant or breast feeding woman or woman of childbearing potential not using adequate birth control
• Known hypersensitivity to any constituent of the study medication or placebo
• Participation in any other investigational study in the last three months
• Subject anticipated not being able to adhere to study plan according to investigator judgement